Looking for a cheap biotech A couple of observations:
1. A lot of bad blood on this board and I understand why.
2. This company is in dire need of cash IF it doesn't monetize the deal announced with Kedrion.
3. The stock might be drifting down on the anticipation of dilutive and necessary financing.
So, for those acquainted with the company:
1. When is the Kedrion money expected to be paid? A lump sum? Scheduled payments?
2. Where does this company stand with their R&D programs?
3. Has the company given any guidance regarding their future cash burn?
Thanks and GLTA